Abstract
Paralleling breast conservation therapy for invasive breast cancers, treatment for ductal carcinoma in situ (DCIS) has followed the treatment paradigm of surgery and postoperative radiotherapy. Randomized studies evaluating the need for radiation therapy following lumpectomy in patients with DCIS from both the NSABP (B-17) and the EORTC (10853) demonstrated a local control benefit that was homogeneous across all treatment groups. In an era of medicine driven by characterization of tumors into molecular subsets and increasingly focused on individualizing treatment, this “one size fits all” mentality has been challenged. With respect to invasive disease, it has become clear that while prospective randomized studies continue to show a reduction in local recurrence with the addition of postoperative radiation therapy, the magnitude of benefit varies among subsets of patients. The variability in the magnitude of benefit from postoperative radiotherapy was additionally demonstrated in a study showing further reduction in recurrence risk with the addition of a boost following whole breast treatment for invasive disease. In DCIS large randomized trials evaluating the additional efficacy of a boost and which subsets of patients would benefit the most, are lacking. While an international trial evaluating the benefit of a boost in patients with DCIS continues to accrue, the question of the risk:benefit ratio with the use of a boost and whom it will best serve remains unanswered.
Keywords: DCIS, breast cancer, radiation therapy, radiation boost, review
Current Cancer Therapy Reviews
Title: The Importance and Evolution of Radiation Dose in DCIS
Volume: 6 Issue: 3
Author(s): Kimberly S. Keene and Jennifer De Los Santos
Affiliation:
Keywords: DCIS, breast cancer, radiation therapy, radiation boost, review
Abstract: Paralleling breast conservation therapy for invasive breast cancers, treatment for ductal carcinoma in situ (DCIS) has followed the treatment paradigm of surgery and postoperative radiotherapy. Randomized studies evaluating the need for radiation therapy following lumpectomy in patients with DCIS from both the NSABP (B-17) and the EORTC (10853) demonstrated a local control benefit that was homogeneous across all treatment groups. In an era of medicine driven by characterization of tumors into molecular subsets and increasingly focused on individualizing treatment, this “one size fits all” mentality has been challenged. With respect to invasive disease, it has become clear that while prospective randomized studies continue to show a reduction in local recurrence with the addition of postoperative radiation therapy, the magnitude of benefit varies among subsets of patients. The variability in the magnitude of benefit from postoperative radiotherapy was additionally demonstrated in a study showing further reduction in recurrence risk with the addition of a boost following whole breast treatment for invasive disease. In DCIS large randomized trials evaluating the additional efficacy of a boost and which subsets of patients would benefit the most, are lacking. While an international trial evaluating the benefit of a boost in patients with DCIS continues to accrue, the question of the risk:benefit ratio with the use of a boost and whom it will best serve remains unanswered.
Export Options
About this article
Cite this article as:
S. Keene Kimberly and De Los Santos Jennifer, The Importance and Evolution of Radiation Dose in DCIS, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698160
DOI https://dx.doi.org/10.2174/157339410791698160 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Feature Selection Using Information Distance Measure for Gene Expression Data
Current Proteomics The Immunomodulating Activities of Resveratrol Glucosides in Humans
Recent Patents on Food, Nutrition & Agriculture Cytoplasmic CXCR4 High-Expression Exhibits Distinct Poor Clinicopathological Characteristics and Predicts Poor Prognosis in Triple-Negative Breast Cancer
Current Molecular Medicine Early-Life Stress and Psychiatric Disorders: Epidemiology, Neurobiology and Innovative Pharmacological Targets
Current Pharmaceutical Design Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Current Drug Delivery Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes
Current Drug Metabolism OMICS-Derived Targets for Inflammatory Gut Disorders: Opportunities for the Development of Nutrition Related Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets Spirooxindoles as Potential Pharmacophores
Mini-Reviews in Medicinal Chemistry Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Proteasome Regulators: Activators and Inhibitors
Current Medicinal Chemistry Liposomes for Pulmonary Drug Delivery: The Role of Formulation and Inhalation Device Design
Current Pharmaceutical Design The Regulation of miRNAs in Inflammation-Related Carcinogenesis
Current Pharmaceutical Design Critical Review of the Evidence on 5-Aminosalicilate for Chemoprevention of Colorectal Cancer in Ulcerative Colitis: A Methodological Question
Current Clinical Pharmacology MADD Expression in Lung Adenocarcinoma and its Impact on Proliferation and Apoptosis of Lung Adenocarcinoma Cells
Combinatorial Chemistry & High Throughput Screening Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Design, Synthesis and Anticancer Evaluation of Acetamides Comprising 1,2,3-triazole, 1,3,4-thiadiazole and Isothiazolo[4,3-b]pyridine Rings
Letters in Organic Chemistry